Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation

Related Clinical Trial
Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis. Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren’s Syndrome, and Graft Vs Host Disease LYell SYndrome MEsenchymal Stromal Cells Treatment Severe Bullous Drug Eruption and Filgrastim Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation Severe Cutaneous Adverse Reactions in Thailand Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS) Stevens-Johnson Syndrome Antimicrobial Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye G-CSF in the Treatment of Toxic Epidermal Necrolysis Corneal Epitheliotropic Factors in Autologous Serum Eye Drops in Nonautoimmune and Stevens-Johnson Syndrome With Dry Eye Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study Topical Infliximab in Autoimmune Eyes With Keratoprosthesis HLA-B*5801 Screening to Prevent Allopurinol-induced Severe Cutaneous Adverse Reaction Drug Reactions Sampling (COLLECTIONTOXIDERMIES) Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN) Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis NATIENS: Optimal Management and Mechanisms of SJS/TEN

Brief Title

Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation

Official Title

A Prospective Open-label, Multicenter Clinical Investigation to Assess the Safety and Performance of ARGOS-IO System in Patients Undergoing Implantation of a Boston Keratoprosthesis (BKPro)

Brief Summary

      The ARGOS-IO pressure sensor is intended to be implanted in the human eye in combination with
      Boston Keratoprosthesis (BKPro) surgery and to remain in place indefinitely. It is intended
      to be used together with the hand-held Mesograph reading device to telemetrically measure the
      intraocular pressure (IOP) of patients with a BKPro.

      The purpose of this study is to evaluate the safety and performance of the ARGOS-IO system in
      patients undergoing concomitant implantation of a BKPro and an ARGOS-IO sensor over the 12
      month period beginning at implantation.

Study Type


Primary Outcome

Safety of the ARGOS-IO pressure sensor in the first 12 months following implantation

Secondary Outcome

 Safety of the ARGOS-IO pressure sensor use in the first 4, 16 and 28 weeks and 12 months following implantation


Graft vs Host Disease


ARGOS-IO system

Study Arms / Comparison Groups

 ARGOS-IO system
Description:  The ARGOS-IO system is a non-European Community (CE) marked investigational medical device composed of the implant and its accessories.
Implant: ARGOS-IO pressure sensor implant for sulcus placement or transcleral fixation
Accessories: MESOGRAPH reading device, Implant Injector


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

March 2015

Completion Date

June 14, 2017

Primary Completion Date

June 14, 2017

Eligibility Criteria

        Inclusion Criteria:

          1. Male or female aged ≥ 18 and ≤ 80 years on the day of screening

          2. Keratoprosthesis surgery indicated, defined as having a severely opaque and
             vascularized cornea AND either a verifiable history of two or more prior failed
             corneal transplant procedures or a medical condition such as alkali burns or
             autoimmune disease that makes the success of a traditional corneal transplant
             procedure unlikely. Potential study subjects will be solicited for participation in
             the clinical trial only after they have consented to the keratoprosthesis operation.

          3. Axial length > 21 mm

          4. Ability and willingness to attend all scheduled visits and comply with all study

        Exclusion Criteria:

          1. Reasonable chance of success with traditional keratoplasty

          2. Current retinal detachment

          3. Connective tissue diseases

          4. History or evidence of severe inflammatory eye diseases (i.e. uveitis, retinitis,
             scleritis) in one or both eyes within 6 months prior to ARGOS-IO implantation

          5. History of ocular or periocular malignancy

          6. History of extensive keloid formation

          7. Any known intolerance or hypersensitivity to topical anesthetics, mydriatics, or
             silicone (component of the device)

          8. Presence of another active medical eye implant and/or other active medical implants in
             the head/neck region

          9. Signs of current infection, including fever and current treatment with antibiotics

         10. Severe generalized disease that results in a life expectancy shorter than a year

         11. Any clinical evidence that the investigator feels would place the subject at increased
             risk with the placement of the device

         12. Currently pregnant or breastfeeding

         13. Participation in any study involving an investigational drug or device within the past
             30 days or ongoing participation in a study with an investigational drug or device

         14. Intraoperative complication that would preclude implantation of the study device

         15. Subject and/or an immediate family member is an employee of the investigational site
             directly affiliated with this study, the sponsor or the contract research

        Previous or concurrent enrollment of the contralateral eye in this clinical study.




18 Years - 80 Years

Accepts Healthy Volunteers



Thomas Neuhann, Prof. MD, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Secondary IDs


Responsible Party


Study Sponsor

Implandata Ophthalmic Products GmbH

Study Sponsor

Thomas Neuhann, Prof. MD, Principal Investigator, MVZ Prof. Neuhann

Verification Date

August 2017